Page 10 of Dr Reddy's Laboratories

Dr Reddy’s launches Nexium generic in US market

Dr Reddy’s Laboratories (DRL) has launched the generic version of Astrazeneca’s Nexium, used to treat acid reflux, in the US…

September 28, 2015 13:07 IST

Dr Reddy’s to buy IP rights of thrombosis drug for $17.5 m

Fondaparinux is a generic version of the anticoagulant drug Arixtra which is used for the treatment of deep vein thrombosis…

September 26, 2015 03:18 IST

Dr Reddy’s Laboratories to buy intellectual property rights of fondaparinux for $17.5 mn

Dr Reddy’s Laboratories on signed an agreement to buy the exclusive intellectual property rights (IPR) of fondaparinux sodium for $17.5…

Updated: September 25, 2015 19:35 IST

Dr Reddy’s Lab, BioMarin settle Kuvan litigation

Kuvan, which clocked $203-m revenues for the company in 2014, is used for the treatment of hyperphenylalaninemia

September 22, 2015 00:38 IST

Dr Reddy’s, BioMarin settle patent litigation on Kuvan tablets

BioMarin will allow the Indian drug maker to market a generic version of Kuvan 100mg tablets in the US at…

September 21, 2015 16:45 IST

DRL partners with PanTheryx

To market PanTheryx’s proprietary nutritional intervention for paediatric infectious diarrhoea PanTheryx, a global medical nutrition company based in Boulder, Colorado…

September 10, 2015 10:51 IST

Stocks that made news today: Vedanta, Suven Life Sciences and more

Suven Life Sciences stocks rose after the company said that it has been granted one patent each in 5 nations,…

Updated: September 10, 2015 17:08 IST

Dr Reddy’s shares fall as its arm recalls Amlodipine besylate and Atorvastatin calcium tablets in US

Share price of Dr Reddy’s Laboratories fell over a per cent in the afternoon trade on Monday on reports that…

Updated: September 7, 2015 16:42 IST

Dr Reddy’s recalls seven batches of tablets in US

The US Food and Drug Administration (USFDA) has said these batches were voluntarily recalled by the company.

September 5, 2015 00:14 IST

Why Indian pharma stocks are performing better than their global counterparts

The double-digit stock market gains of Indian pharmaceutical giants including Dr. Reddy’s Laboratories and Wockhardt stand out in stark relief…

September 3, 2015 09:11 IST

Dr Reddy’s ties up with Arogya Fin to test rural markets

The company said the move aims at helping the rural masses get financing, so that cash flow does not restrict…

August 29, 2015 03:42 IST

Dr Reddy’s North America head quits

Umang Vohra was previously Dr Reddy’s Laboratories’s Chief Financial Officer in India Dr Reddy’s Laboratories North America head Umang Vohra…

August 28, 2015 09:35 IST

Dr Reddy’s North America head quits

Umang Vohra was previously Dr Reddy’s Laboratories’s chief financial officer (CFO) in India.

August 28, 2015 04:08 IST

DRL recalls Rivastigmine Tartrate capsules from US

A total of 60 bottles of 2952 units are recalled on the direction of US FDA

August 20, 2015 16:31 IST

DRL launches Pramipexole dihydrochloride extended-release tablets in US

The tablets are available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes…

August 13, 2015 11:14 IST

Dr Reddy’s to market three Amgen drugs in India

Dr Reddy’s Laboratories said it has inked a pact with US-based biotechnology firm Amgen to market its three drugs used…

August 6, 2015 13:31 IST

DRL in collaboration with Amgen in India

DRL to market and distribute Amgen’s Repatha, Kyprolis and BLINCYTO in India upon approval Dr Reddy’s Laboratories (DRL) has entered…

August 6, 2015 12:09 IST

Dr Reddy’s Lab shares hit a fresh high of Rs 4,325 on collaboration with Amgen

Dr Reddy’s Laboratories shares gained over 2 per cent in the morning trade on Thursday and hit a fresh all…

Updated: August 6, 2015 16:57 IST

Related News

Who is Alexandr Wang? The 28-year-old hired by Mark Zuckerberg for $14 billion to head Meta’s Superintelligence Labs

Aadhaar Card update October 2025: Here’s how to change name, address, date of birth and phone number online in simple steps

Engineer denied B2 visa despite stable job and business, officer says ‘unfortunately you are…’

Kantara Chapter 1 re-writes box office history: All the records Rishab Shetty film has broken so far

LG Electronics IPO updates 2025, LG Electronics IPO live allotment status

LIVE: LG Electronics IPO subscribed 2.95 times so far on Day 2, GMP up 26% – What’s driving the buzz?

Q2 results on October 9; all eyes on H-1B visa impact, rationale of planned layoffs

Business27 min ago

Indian IT sector set for steadier quarter with TCS, HCL Technologies, Persistent Systems, and Tech Mahindra announcing results. Kotak Institutional Equities expects 0.2-6% sequential growth and steady margins. Concerns include H-1B visa rules and impact of weak rupee. Focus on TCS’s planned layoff of 12,000 employees and Infosys’s expected 1.8% growth.

View all shorts